GT Healthcare Capital Partners

At Capstan, we continue our journey to bring minimally invasive options to heart valve patients that need it most. https://lnkd.in/gNCBA5EK

We are excited to announce that EchoGo® Amyloidosis has received Breakthrough Device FDA clearance! Developed in collaboration with Johnson & Johnson Innovative Medicine and with support from Pfizer, EchoGo® Amyloidosis is the first FDA-cleared AI screening tool designed to help detect amyloidosis from an echocardiogram. The clearance was achieved as part of Ultromics' participation in the pilot of the FDA’s Total Product Lifecycle Advisory Program (TAP) and is the first device enrolled in TAP to receive FDA marketing authorization. EchoGo® Amyloidosis is part of Ultromics’ EchoGo® platform, complementing our reimbursable EchoGo® Heart Failure device to provide a robust solution for diagnosing heart failure and its underlying causes. Cardiac Amyloidosis is a rare and underdiagnosed cause of heart failure, with up to two-thirds of cases missed. The consequences are severe, but this breakthrough technology can facilitate detection: “𝗥𝗲𝗾𝘂𝗶𝗿𝗶𝗻𝗴 𝗼𝗻𝗹𝘆 𝗮 𝘀𝗶𝗻𝗴𝗹𝗲 𝗮𝗽𝗶𝗰𝗮𝗹 𝟰 𝗰𝗵𝗮𝗺𝗯𝗲𝗿 𝗶𝗺𝗮𝗴𝗲, 𝗘𝗰𝗵𝗼𝗚𝗼® 𝗔𝗺𝘆𝗹𝗼𝗶𝗱𝗼𝘀𝗶𝘀 𝗶𝗱𝗲𝗻𝘁𝗶𝗳𝗶𝗲𝘀 𝗖𝗮𝗿𝗱𝗶𝗮𝗰 𝗔𝗺𝘆𝗹𝗼𝗶𝗱𝗼𝘀𝗶𝘀, 𝗮𝗻𝗱 𝘄𝗶𝗹𝗹 𝗵𝗲𝗹𝗽 𝗱𝗿𝗶𝘃𝗲 𝗲𝗮𝗿𝗹𝗶𝗲𝗿 𝗮𝗰𝗰𝗲𝘀𝘀 𝘁𝗼 𝗮𝗽𝗽𝗿𝗼𝗽𝗿𝗶𝗮𝘁𝗲 𝘁𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁 𝗮𝗻𝗱 𝗰𝗮𝗿𝗲 𝗳𝗼𝗿 𝗽𝗮𝘁𝗶𝗲𝗻𝘁𝘀 𝘄𝗶𝘁𝗵 𝘁𝗵𝗶𝘀 𝘂𝗻𝗱𝗲𝗿𝗱𝗶𝗮𝗴𝗻𝗼𝘀𝗲𝗱 𝗱𝗶𝘀𝗲𝗮𝘀𝗲." - 𝗥𝗼𝘀𝘀 𝗨𝗽𝘁𝗼𝗻, 𝗣𝗵𝗗, 𝗙𝗼𝘂𝗻𝗱𝗲𝗿, 𝗖𝗘𝗢 𝗮𝗻𝗱 𝗖𝗵𝗶𝗲𝗳 𝗦𝗰𝗶𝗲𝗻𝘁𝗶𝗳𝗶𝗰 𝗢𝗳𝗳𝗶𝗰𝗲𝗿, 𝗨𝗹𝘁𝗿𝗼𝗺𝗶𝗰𝘀, 𝗮𝗻𝗱 𝗔𝗜 𝗖𝗼-𝗖𝗵𝗮𝗶𝗿, 𝗛𝗲𝗮𝗿𝘁𝗦𝗵𝗮𝗿𝗲, 𝗙𝗡𝗜𝗛. Learn more: https://lnkd.in/eDFf-pA4 #Ultromics #EchoGo #JNJ #Pfizer #MayoClinic #PrecisionDetection #CardiacAmyloidosis #Amyloidosis #AL #ATTR #EchoFirst #Echocardiography #Cardiovascular #Cardiology #AIinHealthcare #HealthTech #Innovation 

Great team, technology and investors!

Exciting News! We’re thrilled to announce that OrganOx has entered into an exclusive clinical co-development agreement with eGenesis. This partnership aims to advance a novel liver support system integrating the OrganOx ELC with whole biologic livers to address a major unmet need in acute liver failure. Read more about the partnership below. https://lnkd.in/gZkYyiAz

Very honored to share that Moon Surgical has been recognized with the "Convergent Technologies: MedTech, Digital, & Diagnostics" award at the Pantheon Awards, hosted by the California Life Sciences (CLS) Association! 🏆 Moon Surgical illustrates convergence in many different ways. Our diverse team and culture represent many nationalities spread across two continents. Laparoscopy and robotics are brought together into a fully integrated approach. Existing workflows, techniques and instrumentation are combined with edge computing and AI-powered capabilities. The patient and the surgeon are back together at the center of the operating room. 🚀   Our Maestro System continues to support surgeons in treating more patients daily, shaping a digitalized future for surgery. It’s an exhilarating time for Moon Surgical and the evolving operating room ! Thank you to California Life Sciences for this recognition and to our remarkable team for driving forward this mission. And congratulations to our star Chief Technical Officer, David Noonan, for looking so good in a suit and delivering our recipient speech ! ⭐   #innovation #surgery #digitalhealth #lifesciences Jeffery Alvarez Anne Renevot Viola F. Josh Christensen Eric Ermenault Frederic Moll Sofinnova Partners MD Start

IN THE NEWS: We’re excited to share that ZAP Surgical has successfully closed a $78 million Series E funding round! The round was led by Baheal Medical Inc., with support from other strategic investors. This new funding will help accelerate the commercialization of ZAP-X Gyroscopic Radiosurgery, a groundbreaking platform that is transforming the future of brain surgery. Read the full press release here: https://lnkd.in/ev6nvdxH #radiotherapy #roboticsurgery #radiosurgery #neurosurgery #radiotherapy #radiationtherapy #radiationoncology #medtech #healthtech #zapx

We're pleased to share that the FDA has cleared our IND application for ABX-002 as an adjunctive treatment for bipolar depression.    This is a meaningful step in our efforts to advance innovative therapies for #CNSdisorders and expands our #depression program with ABX-002, which is currently being evaluated in the AMPLIFY Phase 2 trial for #majordepressivedisorder. We plan to initiate a Phase 2 trial of ABX-002 in bipolar depression by the end of 2024.   For more details: https://lnkd.in/g3jfZp-u   #BipolarDepression #MentalHealth #Biotech

🚀We’re excited to announce that we’ve received IND clearance from the NMPA for GTA182, our next-generation, MTA-cooperative PRMT5 inhibitor for the treatment of MTAP-null solid tumors. Preclinical studies have demonstrated a substantially expanded therapeutic window in models such as glioblastoma and other non-CNS cancers with MTAP deletions. As Fred Aswad, Ph.D., Co-Founder and SVP, stated: “GTA182 represents a significant advance in targeting MTAP-null tumors. Our preclinical data shows compelling tumor growth inhibition and regression in multiple models, including glioblastoma, one of the most challenging cancers to treat.” We’re excited to initiate our Phase 1a/b trial and preparing to file an IND with the US FDA in 2025!🎉 🎊 #INDclearance #GTA182 #Oncology #PRMT5 #MTAPNull #Glioblastoma #PrecisionMedicine #CancerResearch #Clinicaltrials #DrugDiscovery #FDA

We are very proud to announce the approval of the metra in Canada for commercial use, marking an exciting milestone in our mission to increase the number of donor organs available and improving outcomes. In support of the product launch next year, our team will be attending the Canadian Transplant Society (CTS) Congress later this month. We look forward to connecting with clinicians and discussing how together, we can make a difference in liver transplantation. Further information can be found on this press release. #TransplantSurgery #metra #organox #LiverTransplant 

Real-World Evidence (#RWE) has the potential to offer significant benefit in the development of new medicines by enhancing understanding of patient populations, shortening drug development timelines and providing robust evidence on the effectiveness and safety of new treatments in real world settings.   During a recent discussion with Paul Gough, Partnership and Projects Manager at Great Ormond Street Hospital for Children NHS Foundation Trust and GOSH DRIVE, our Head of NHS Partnerships, Alistair Armstrong reflects on how the Arcturis partnership network of leading #NHS trusts and the wider ecosystem is successfully working together to realise these benefits by curating real-world datasets that support ground breaking medical research.   If you are an NHS Trust or representative interested in working with us, please reach out at info@arcturisdata.com #realworlddata #gosh #greatormondstreet #healthcareinnovation #arcturis #nhspartner